AKT1 and neoplasm: Similarly, G9a inhibitors UNC0642 and UNC0638 sensitize resistant NSCLC cells in vivo to TKIs by inhibiting the AKT pathway, and their combination with erlotinib markedly suppresses tumor growth in transplanted mice (40).